985 results on '"Hassel, Jessica C"'
Search Results
2. Nebenwirkungsmanagement bei Immuncheckpointinhibition: Schwerpunkt „Nebenwirkungsmanagement“
3. Nebenwirkungsmanagement bei Immuncheckpointinhibition
4. Nebenwirkungen dermatoonkologischer Therapien
5. Nebenwirkungen onkologischer Therapien
6. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
7. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
8. Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
9. Uveamelanome
10. Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level
11. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
12. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
13. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
14. Fertilität, Kontrazeption und Teratogenität bei Immuncheckpointblockade
15. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
16. Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
17. Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma
18. Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma
19. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
20. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
21. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
22. Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
23. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
24. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
25. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
26. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
27. Targeted Therapy for Melanomas Without BRAF V600 Mutations
28. Fertilitätserhalt beim Melanom – eine große Entlastung der Betroffenen
29. Bimodal intensity-modulated radiotherapy in combination with carbon ion therapy (C12) of mucosal melanomas - data of the last decade from Heidelberg University Hospital.
30. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
31. An online decision aid for patients with metastatic melanoma—results of the randomized controlled trial „PEF-Immun“
32. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
33. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
34. Managing toxicities of immune checkpoint inhibitors
35. Cancer School – kostenfreie Onlineseminare für Krebsbetroffene, Angehörige und Interessierte
36. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
37. Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
38. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
39. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
40. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
41. Nebenwirkungsmanagement bei Immuncheckpointinhibition
42. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
43. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
44. Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).
45. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.
46. Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
47. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
48. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
49. Melanoma brain metastases – Interdisciplinary management recommendations 2020
50. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.